TEMODAR

LOE Approaching

temozolomide

NDAINTRAVENOUSPOWDER
Approved
Feb 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Started Apr 2026
162 enrolled
Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more
NCT06991101Phase 2Recruiting

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Started Dec 2025
190 enrolled
GlioblastomaBrain CancerGlioblastoma Multiforme+4 more
NCT07243470Phase 1/2Recruiting

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Started Nov 2025
70 enrolled
GliomaCNS Tumor, AdultCNS Tumor, Childhood
NCT07215910Phase 3Not Yet Recruiting

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Started Oct 2025
408 enrolled
Astrocytoma, IDH-Mutant, Grade 3
NCT06721689Phase 1/2Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Started Mar 2025
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.